Home › Cancro dell'endometrio › Ohio
Studi clinici su Cancro dell'endometrio nello stato di Ohio
50 studi su Cancro dell'endometrio cercano partecipanti presso sedi nello stato di Ohio.
Città nello stato di Ohio
- Columbus25 studi
- Cleveland20 studi
- Cincinnati13 studi
- Toledo8 studi
- Dayton7 studi
- Akron6 studi
- Parma4 studi
- Mentor3 studi
Testo ufficiale dello studio (inglese)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- OhioHealth O'Bleness Hospital, Athens
- UH Seidman Cancer Center at UH Avon Health Center, Avon
- UHHS-Chagrin Highlands Medical Center, Beachwood
- e altri 39
In reclutamentoFase 2
Tutte le età · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05564377Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
- Cleveland Clinic Foundation, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 1
Età 18 e oltre · Donne · Aggiornato il 2 ott 2026 · NCT05950464The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- The Cleveland Clinic Taussig Cancer Center, Cleveland
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04585750Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- OhioHealth O'Bleness Hospital, Athens
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Aultman Health Foundation, Canton
- e altri 19
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 2 ott 2026 · NCT07198074A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Cleveland Clinic - Oncology Department, Cleveland
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06760819A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 06, Maumee
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT07814248Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Cleveland Clinic, Cleveland
In reclutamentoStudio osservazionale
Età 18 e oltre · Donne · Aggiornato il 29 set 2026 · NCT05051722Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Miami Valley Hospital South, Centerville
- Geauga Hospital, Chardon
- e altri 8
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 28 set 2026 · NCT05112601Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Cleveland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT05867251DESTINY-PANTUMOUR04
- Research Site, Canton
- Research Site, Maumee
In reclutamentoStudio osservazionale
Età da 18 a 130 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07124000Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- The Ohio State University Wexner Medical Center, Columbus
In reclutamentoFase 1/2
Età 18 e oltre · Donne · Aggiornato il 25 set 2026 · NCT03564340A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- The Ohio State University Wexner Medical Center, Columbus
In reclutamentoFase 1/2
Età 18 e oltre · Donne · Aggiornato il 24 set 2026 · NCT04590326Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Geauga Hospital, Chardon
- Case Western Reserve University, Cleveland
- e altri 4
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 24 set 2026 · NCT05640999Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Cincinnati
- Research Site, Columbus
In reclutamentoFase 2
Età da 18 a 130 · Tutti i sessi · Aggiornato il 23 set 2026 · NCT05489211A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Miami Valley Hospital South ( Site 6014), Centerville
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007), Columbus
- Kettering Health Main Campus-Kettering Health Cancer Center ( Site 5001), Kettering
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 17 set 2026 · NCT06952504A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- UH Cleveland Medical Center, Cleveland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07109726A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- Miami Valley Hospital South, Centerville
- Ohio State University, Hilliard
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 17 set 2026 · NCT06340568A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
- GSK Investigational Site, Canton
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT07213609ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cleveland Clinic, Cleveland
- Toledo Clinic Cancer Center, Toledo
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT05059444Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- University of Cincinnati Medical Center, Cincinnati
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 9 set 2026 · NCT07166094A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The Ohio State University (OSU) Wexner Medical Center, Columbus
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT06400472DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Cincinnati
- Research Site, Columbus
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 3 set 2026 · NCT06989112Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- The Ohio State University, Columbus
In reclutamentoFase 1
Età 15 e oltre · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT06276491Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
In reclutamentoFase 1/2
12 Months – 30 Years · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT04851119A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Cleveland Clinic Taussig Cancer Institute, Cleveland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 ago 2026 · NCT06774963Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Columbus
In reclutamentoFase 1/2
Età da 18 a 130 · Tutti i sessi · Aggiornato il 21 ago 2026 · NCT05797168A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- Miami Valley Hospital South, Centerville
- University of Cincinnati Cancer Center, Cincinnati
- Ohio State University, Hilliard
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 21 ago 2026 · NCT05548296A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Maumee
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT07182149A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- Ohio State University Wexner Medical Center, Columbus
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT07470853FOG-001 in Locally Advanced or Metastatic Solid Tumors
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland
- Cleveland Clinic, Cleveland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT05919264A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 ago 2026 · NCT05592626Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
- University Hospital - Cleveland Medical Center, Cleveland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ago 2026 · NCT07444814Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 ago 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Oncology Hematology Care Primary, Cincinnati
- Taylor Cancer Research Center, Maumee
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 lug 2026 · NCT04657068Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Cincinnati
- Research Site, Cleveland
- Research Site, Cleveland
- e altri 4
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 29 lug 2026 · NCT07044336Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
- University of Cincinnati Physicians Group, LLC, Cincinnati
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 28 lug 2026 · NCT07022483A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 lug 2026 · NCT05208762Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 304, Centerville
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 16 lug 2026 · NCT06906341First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- UH Cleveland Medical Center, Cleveland
- Stefanie Spielman Comprehensive Breast Center, Columbus
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 lug 2026 · NCT05768139Integrated Cancer Repository for Cancer Research
- Aultman Alliance Community Hospital, Alliance
- Aultman Hospital, Canton
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 19 a 110 · Tutti i sessi · Aggiornato il 29 giu 2026 · NCT02012699Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.